Appendic cancer is very rare, accounting for less than 1% of gastrointestinal tumors, and there is little scientific data on the disease, which means that the current guidelines for the treatment of colon cancer are recommended for patients with appendic cancer. To understand why some patients with appendix cancer respond to standard treatment for colon cancer, while others do not, the researchers performed a genetic analysis of 703 appendix cancer samples. This is by far the largest study of appendix cancer to compare the mutations present in the two cancer types.
Mhedzisiro yechidzidzo ichi yakasimbisa kuti genetic mutations mune appendix cancer yakasiyana neiyo mucolon cancer. TP53 uye GNAS shanduko dzakanaka kufungidzira kwekupona muvarwere vane appendix cancer. Kune asingawanzo appendix cancers, kuwana mamepu emamorekuru kuchabatsira kuona zvingangoitwa kurapwa nekuti isu hatina data rekiriniki rekuyedza kutungamira kurapwa kwakajairwa semamwe magomarara. Zvakatonyanya kukosha, iyo mutation spectrum inogona kushandiswa sebiomarker kusiyanisa varwere vari panjodzi huru vanoda kurapwa kwakanyanya kuti vavaparadzanise nevarwere vane njodzi shoma.
Ongororo yekuongorora yakawana kuti appendix cancer inosanganisira zvishanu zvakasiyana: mucinous adenocarcinoma (46%), adenocarcinoma (30%), goblet cell carcinoma (12%), peritoneal pseudomyxoma (7.7%), uye signet ring Cell carcinoma (5.2%). GNAS gene mutations isingawanzo mucolon cancer yakajairika muappendix cancer, kunyanya mucinous adenocarcinoma (52%) uye peritoneal pseudomyxoma (72%). Kupona kwepakati kwevarwere vane mapundu ane GNAS mutations angangoita makore gumi, nepo kurarama kwepakati kwevarwere vane tumors vane TP10 mutations imakore matatu chete, uye kurarama kwepakati kwevarwere vasina aya maviri emajini ekuchinja makore matanhatu.
This surprising discovery raises the question of whether patients with early-stage GNAS-mutant tumors need to be treated with chemotherapy because it may be cured by surgery alone, so more research is needed to prove it.
